Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study.
The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 x 10(9)/l neutrophils of 10 days (range 8-13) and 20 x 10(9)/l platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.
Imai
Y
Y
Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Chou
T
T
Tobinai
K
K
Tanosaki
R
R
Morishima
Y
Y
Ogura
M
M
Shimazaki
C
C
Taniwaki
M
M
Hiraoka
A
A
Tanimoto
M
M
Koike
T
T
Kogawa
K
K
Hirai
H
H
Yoshida
T
T
Tamura
K
K
Kishi
K
K
Hotta
T
T
D000328:Adult; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002999:Clone Cells; D005260:Female; D015321:Gene Rearrangement; D006085:Graft Survival; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D018189:Immunomagnetic Separation; D016130:Immunophenotyping; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D016133:Polymerase Chain Reaction; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D007143:Immunoglobulin Heavy Chains